Cigna Stock Performance: A Closer Look
Shares of The Cigna Group (CI) are up 25.6% over the past year, comfortably ahead of the industry’s 18.2% gain. For context, the broader Medical sector rose 9.3% in that span, while the S&P 500 advanced 21.2%. That kind of outperformance reflects a sturdy member base, steady contributions from Evernorth, well-timed acquisitions, and a growing cash cushion that gives the company flexibility.
At $357.40, Cigna trades just 3.6% below its 52-week high of $370.64. Sitting that close to a high often signals firm investor confidence and an expectation that the company’s opportunity set remains attractive.
Even with a current Zacks Rank of #3 (Hold), Cigna has topped earnings expectations in each of the last four quarters, delivering an average surprise of 3.83%. Consistency like that tends to build credibility with investors, quarter after quarter.
What Analysts Expect Next
The Zacks Consensus Estimate points to 2024 earnings of $28.48 per share, a 13.5% increase from 2023. Revenue is projected at $239.1 billion, which would be a substantial 22.4% year-over-year rise.
Looking to 2025, the earnings estimate moves up to $31.80 per share, implying 11.7% growth over 2024. Revenue is expected to reach $246.5 billion, a further 3.1% increase from the prior year’s projection.
What’s Fueling Cigna’s Growth
Two engines drive results: Evernorth and Cigna Healthcare. Evernorth, which includes specialty pharmacy services, has been a standout. Pharmacy revenue jumped 31.8% year over year in the first half of 2024, underscoring the strength of that platform and its role in Cigna’s broader growth plan.
Cigna Healthcare benefits from a sizable U.S. customer base and a long-term adjusted earnings growth target of 7–10% annually. As of mid-2024, the company serves roughly 19 million medical customers. An aging U.S. population is expected to lift demand for Medicare plans, a trend that can help steady and expand revenue over time.
Pricing tailwinds, ongoing product innovation, and new partnerships with leading health systems continue to strengthen Cigna’s positioning. The company also uses acquisitions to widen capabilities and reach, while shedding non-core health units to focus capital and attention on areas with higher growth potential.
With solid cash generation, Cigna has room to fund expansion, repurchase shares, and raise dividends. Management expects approximately $60 billion in cumulative cash flows over the next five years, supporting those priorities.
Other Medical Names to Watch
Investors scanning the Medical space might also consider Universal Health Services, Inc. (UHS), The Ensign Group, Inc. (ENSG), and HCA Healthcare, Inc. (HCA). Universal Health carries a Zacks Rank #1 (Strong Buy), while Ensign Group and HCA Healthcare are both Zacks Rank #2 (Buy).
Universal Health has topped the Zacks Consensus Estimate in each of the last four quarters, with an average surprise of 14.58%. For 2024, earnings are projected to climb 51% year over year, and revenue is expected to grow 9.8%.
The Ensign Group has also exceeded expectations, delivering an average earnings surprise of 1.40%. Its 2024 outlook calls for a 14.1% increase in earnings and a 13.1% rise in revenue versus last year.
HCA Healthcare beat earnings estimates in three of the last four quarters. Its 2024 growth forecast suggests an 18.2% improvement over the prior year.
Conclusion
Cigna stands out in the medical industry with clear growth drivers, strong execution, and supportive cash flow. While no stock moves in a straight line, the company’s operational momentum and financial outlook give investors reasons to stay engaged with Cigna (CI) as they navigate what comes next.
Frequently Asked Questions
How has Cigna’s stock performed over the last year?
It’s up 25.6% year over year, outpacing the industry’s 18.2% gain, the Medical sector’s 9.3% rise, and the S&P 500’s 21.2% increase.
Where is the stock trading relative to its 52-week high?
Cigna closed at $357.40, which is 3.6% below its 52-week high of $370.64—near the top of its range.
What are the current earnings and revenue estimates for 2024 and 2025?
For 2024, the consensus calls for $28.48 per share in earnings and $239.1 billion in revenue. For 2025, estimates rise to $31.80 per share and $246.5 billion in revenue.
Which business segments are driving results?
Evernorth (including specialty pharmacy) and Cigna Healthcare. Evernorth saw pharmacy revenue grow 31.8% year over year in the first half of 2024, while Cigna Healthcare benefits from a large U.S. customer base and a 7–10% long-term adjusted earnings growth target.
What other medical stocks are worth a look right now?
Universal Health Services (UHS), The Ensign Group (ENSG), and HCA Healthcare (HCA) are notable, with UHS at Zacks Rank #1 and both ENSG and HCA at Zacks Rank #2.
